Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.

Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.

Tenofovir-emtricitabine (TDF-FTC) pre-exposure prophylaxis (PrEP) has been found to be effective for prevention of HIV infection in several clinical trials. Two studies of TDF PrEP among men who have sex with men showed slight bone mineral density (BMD) loss. We investigated the effect of TDF and th...

Full description

Bibliographic Details
Main Authors: Michael Kasonde, Richard W Niska, Charles Rose, Faith L Henderson, Tebogo M Segolodi, Kyle Turner, Dawn K Smith, Michael C Thigpen, Lynn A Paxton
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3953113?pdf=render

Internet

http://europepmc.org/articles/PMC3953113?pdf=render

Similar Items